ReviewInternational journal of molecular sciences2020
Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Structure based in silico screening of natural Vitamin D analogs for targeted and safer treatment of resistant multiple sclerosis.Scientific reports · 2025Article
- Vitamin D receptor gene polymorphisms in patients with relapsing multiple sclerosis.European journal of translational myology · 2025Article
- Article
- An Overview of Multiple Sclerosis In Vitro Models.International journal of molecular sciences · 2024Review
- Enhancing Human Treg Cell Induction through Engineered Dendritic Cells and Zinc Supplementation.Critical reviews in immunology · 2024Article
- Vitamin D-An Effective Antioxidant in an Animal Model of Progressive Multiple Sclerosis.Nutrients · 2023Article
- Magnesium and the Brain: A Focus on Neuroinflammation and Neurodegeneration.International journal of molecular sciences · 2022Review
- Inflammation- and Gut-Homing Macrophages, Engineered toInternational journal of molecular sciences · 2021Article
- Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol.International journal of molecular sciences · 2021Article
- Vitamin D in Multiple Sclerosis-Lessons From Animal Studies.Frontiers in neurology · 2021Review
- Editorial: Immune-Modulatory Effects of Vitamin D.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and is caused by an aberrant immune response to myelin sheath. Disease-modifying medications, which mainly aim to suppress such aberrant immune response, have significantly improved MS treatment. However, the disease severity continues to worsen. In contrast, progressively more data suggest that 1,25-dihydroxyvitamin D or 1,25(OH)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.